Quick Answer
LENZ Therapeutics, Inc. reported Stockholders Equity of $284.34 million for the year ending 2025.
- LENZ Therapeutics, Inc. showed an increase of +39.3% in Stockholders Equity from 2024 to 2025.
- This data is from LENZ Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$2.36 million | Q2 2020: -$1.45 million | Q3 2020: -$4.79 million | Q1 2021: -$84.08 million | Q2 2021: $379.18 million | Q3 2021: $400.13 million | Q1 2022: $361.30 million | Q2 2022: $338.46 million | Q3 2022: $316.45 million | Q1 2023: -$36.68 million | Q2 2023: -$51.21 million | Q3 2023: -$69.57 million | Q1 2024: $198.17 million | Q2 2024: $192.92 million | Q3 2024: $215.28 million | Q1 2025: $192.01 million | Q2 2025: $206.37 million | Q3 2025: $193.93 million.
- Over the full 7 years of available data (2019 to 2025), LENZ Therapeutics, Inc.'s Stockholders Equity has grown by 12,919.6%.
- Historical annual values: Fiscal year 2025: $284.34 million | Fiscal year 2024: $204.08 million | Fiscal year 2023: -$92.71 million | Fiscal year 2022: -$24.17 million | Fiscal year 2021: $384.05 million | Fiscal year 2020: -$65.41 million | Fiscal year 2019: -$2.22 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: